
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci Corp's lead product candidate, ABS-201, demonstrates promising potential for significant hair growth in patients, with management indicating that achieving a target of at least 40 hairs/cm² would position it competitively in the market. The anticipated initial efficacy data from the MAD study, expected in the second half of 2026, represents a crucial milestone that could further validate the product's therapeutic capabilities and drive investor interest. The updated real net present value (rNPV) of $1.6 billion, an increase from the previous $1.4 billion, reflects growing confidence in the product's commercial viability and strong preclinical evidence supporting its mechanism of action.
Bears say
Absci Corp faces multiple risks that could adversely impact its stock performance, including challenges related to partnerships, technology, clinical development, regulatory hurdles, and potential competition. Additionally, there are significant concerns surrounding the company's ability to maintain and protect its intellectual property while navigating a landscape that may also involve legal complexities. The existing high treatment burden associated with their lead product candidate, ABS-201, may result in patient attrition as individuals gravitate towards more permanent solutions, which could hinder commercial viability and future revenue growth.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares